BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kailasam A, Mittal SK, Agrawal DK. Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma. Clin Transl Sci 2015;8:394-402. [PMID: 25388215 DOI: 10.1111/cts.12242] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Mittal SK, Abdo J, Adrien MP, Bayu BA, Kline JR, Sullivan MM, Agrawal DK. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. J Gastrointest Oncol 2021;12:1197-214. [PMID: 34532080 DOI: 10.21037/jgo-21-117] [Reference Citation Analysis]
2 Abdo J, Bertellotti CA, Cornell DL, Agrawal DK, Mittal SK. Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol 2017;7:151. [PMID: 28770168 DOI: 10.3389/fonc.2017.00151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Abdo J, Agrawal DK, Mittal SK. "Targeted" Chemotherapy for Esophageal Cancer. Front Oncol 2017;7:63. [PMID: 28421164 DOI: 10.3389/fonc.2017.00063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
4 Islam F, Tang JC, Gopalan V, Lam AK. Epigenetics: DNA Methylation Analysis in Esophageal Adenocarcinoma. In: Lam AK, editor. Esophageal Adenocarcinoma. New York: Springer; 2018. pp. 247-56. [DOI: 10.1007/978-1-4939-7734-5_21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 2016;7:48644-55. [PMID: 27102294 DOI: 10.18632/oncotarget.8777] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mahmoudian RA, Farshchian M, Abbaszadegan MR. Genetically engineered mouse models of esophageal cancer. Exp Cell Res 2021;406:112757. [PMID: 34331909 DOI: 10.1016/j.yexcr.2021.112757] [Reference Citation Analysis]
7 Fanelli GN, Gasparini P, Coati I, Cui R, Pakula H, Chowdhury B, Valeri N, Loupakis F, Kupcinskas J, Cappellesso R, Fassan M. LONG-NONCODING RNAs in gastroesophageal cancers. Noncoding RNA Res 2018;3:195-212. [PMID: 30533569 DOI: 10.1016/j.ncrna.2018.10.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
8 Barsouk A, Rawla P, Hadjinicolaou AV, Aluru JS, Barsouk A. Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers. Med Sci (Basel) 2019;7:E100. [PMID: 31561465 DOI: 10.3390/medsci7100100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
9 Gaponova AV, Deneka AY, Beck TN, Liu H, Andrianov G, Nikonova AS, Nicolas E, Einarson MB, Golemis EA, Serebriiskii IG. Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Oncotarget 2017;8:19156-71. [PMID: 27863405 DOI: 10.18632/oncotarget.13353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
10 Wei H, Liu Z, She H, Liu B, Gu J, Wei D, Zhang X, Wang J, Qi S, Ping F. Promoter methylation and expression of Raf kinase inhibitory protein in esophageal squamous cell carcinoma. Oncol Lett 2017;13:1866-72. [PMID: 28454336 DOI: 10.3892/ol.2017.5617] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Caspa Gokulan R, Garcia-Buitrago MT, Zaika AI. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochim Biophys Acta Rev Cancer 2019;1872:37-48. [PMID: 31152823 DOI: 10.1016/j.bbcan.2019.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Zhu X, Luo X, Feng G, Huang H, He Y, Ma W, Zhang C, Zeng M, Liu H. CENPE expression is associated with its DNA methylation status in esophageal adenocarcinoma and independently predicts unfavorable overall survival. PLoS One 2019;14:e0207341. [PMID: 30716092 DOI: 10.1371/journal.pone.0207341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
13 Chen X, Hu H, Liu J, Yang Y, Liu G, Ying X, Chen Y, Li B, Ye C, Wu D, Duan S. FOXF2 promoter methylation is associated with prognosis in esophageal squamous cell carcinoma. Tumour Biol 2017;39:1010428317692230. [PMID: 28222662 DOI: 10.1177/1010428317692230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]